

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/159261 A1

(51) International Patent Classification:

C07C 235/38 (2006.01) A61P 13/12 (2006.01)
A61K 31/196 (2006.01) A61P 29/00 (2006.01)
A61P 9/04 (2006.01) A61P 35/00 (2006.01)

Gareth; c/o Certa Therapeutics Pty Ltd, 31 Queen Street, Melbourne, Victoria 3000 (AU). MITCHELL, Lorna; c/o Certa Therapeutics Pty Ltd, 31 Queen Street, Melbourne, Victoria 3000 (AU).

(21) International Application Number:

PCT/AU2023/051332

(74) Agent: FB RICE PTY LTD; Level 11, 1 Eagle Street, Brisbane, Queensland 4000 (AU).

(22) International Filing Date:

20 December 2023 (20.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023900229 31 January 2023 (31.01.2023) AU
18/354,467 18 July 2023 (18.07.2023) US
18/537,184 12 December 2023 (12.12.2023) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(71) Applicant: CERTA THERAPEUTICS PTY LTD [AU/AU]; 31 Queen Street, Melbourne, Victoria 3000 (AU).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(72) Inventors: KELLY, Darren; c/o Certa Therapeutics Pty Ltd, 31 Queen Street, Melbourne, 3000 (AU). LEWIS,

(54) Title: SOLID FORMS, SALTS AND POLYMORPHS OF ANTI-FIBROTIC COMPOUNDS




Figure 1

(57) Abstract: The present disclosure relates to solid forms and salts, crystalline and otherwise, of (E)-2-[[3-(3-methoxy-4-propargyloxy)phenyl]-1-oxo-2-propenyl]amino]benzoic acid and pharmaceutical compositions comprising same. The use of such solid forms, salts, and pharmaceutical compositions, for treating, preventing, or ameliorating diseases or conditions associated with fibrosis, inflammation and/or proliferation are disclosed.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*